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The golden age of antibiotics in the 1940s and 1950s 
led many scientists to the belief that infectious disease 
as a cause of patient morbidity and mortality was soon 
to become a thing of the past. Today we have a some- 
what more dispassionate opinion, as dealing with the 
problems of antibiotic drug resistance has become an 
everyday task within the hospital. In many commonly 
encountered bacterial species, such as Stqliylococcus 
awtu, Streptorornrspneunionine and several of the Entero- 
bacteriaceae, once uniformly susceptible to most classes 
of antibiotics uted against them, resistance is common- 
place. There have been instances where isolates have 
proved refractory to every potentially active conipound 
in the pharmacy, essentially resulting in untreatable 
infections, a scenario reniiniscent of the pre-antibiotic 
era. While these are extreme, rare examples, in almost 
every bacterial species acquired or emerging resistance 
to one or several drugs has been reported somewhere 
in the world [1,3]. From both scientific and public- 
health perxpectives, it is imperative that we maintain an 
awareness of emerging bacterial drug resistance. Both 
the government and scientific conimunity should be 
united in appreciating the need for methods in global 
surveillance of antimicrobial resistance to achieve this 
[3,1]. While coiiseiisus opinion on these factors is the 
first easy step, more problematic is how to implement 
and achieve an appropriate surveillance system that 
fulfills the needs of scientists, healthcare workers and 
public-health organizations. The ideal system should 
make possible the long-term surveillaiice and tracking 
of antibiotic resistance trends, be able to alert healthcare 
professionals to novel resistance profiles rapidly and on 
a daily basis, identify emerging resistance patterns, and 
enable scientists and prescribing clinicians alike to access 
the database at  any time for comprehensive review and 
analysis. Such a system would provide resistance data 
which, when linked with supportive research programs 
in infection control and pharmaceutical usage, would 
allow for the development of practical measures 
designed to h i i t  and ultimately reduce the burden of 
antibiotic resistance, at both local and national levels. 
To accomplish these objectives, the surveillance system 
would be prospective, comprehensive, responsive and 
necessarily automated and computerized. With the 
appropriate investment, today’s advances in computer 
technology and communications make this possible. 
A resistance surveillance effort is, in effect, gather- 
ing together susceptibility data and relevant clinical 
data, in order to create databases for subsequent analysis. 
To date, most surveyed susceptibility data within Europe 
have been derived from targeted ‘point-in-time’ pro- 
jects focused on a particular subset of organisms or class 
of antibiotics, or via some of the larger surveillance 
studies deriving data from centralized or decentralized 
in vitro studies where organisms are gathered and retested 
using predefined panels of study antibiotics (e.g. 
the Alexander Project, SENTRY). The pharmaceutical 
manufacturing industry has played a crucial role in 
sponsoring many of these studies. For practical 
purposes, such labor-intensive studies have generally 
focused on particular sites of infection or subsets of 
organisms, or included a defined range of target 
drugs, which often includes investigational proprietary 
comparator antibiotics. Together, these have provided 
a wealth of susceptibility data, often standardized 
methodologically, which in Europe has been otherwise 
largely unobtainable. However, it is fair to say that 
across Europe such Surveillance studies provide a 
somewhat limited ‘early-warning system’ and a poor 
ability to respond to what may be emerging trends in 
resistance. For example, recent work by Tenover et al. 
has suggested that the subset of methicillin-resistant 
61 
6 2  C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  5 N u m b e r  2 ,  F e b r u a r y  1999 
Staplzylococctrs au~eus  and other staphylcoccal species 
with an MIC of 4 mg/L for vancomycin are those most 
likely to go on to undergo further incremental 
decreases in susceptibility to this drug [5]. However, in 
Europe we do not have a system that enables us to 
respond to this information and ascertain the popu- 
lation and epidemiology of such phenotypes, despite 
the fact that thousands of staphylococci are identified 
and susceptibility tested to vancomycin in our labora- 
tories daily. 
An appropriate surveillance network must en- 
compass a broad coverage of clinical microbiological 
institutes in the proposed region of study. If not all- 
encompassing (bearing in mind there are several 
thousand such laboratories in Europe), the system 
should at least be representative ofall types and sizes of 
institution. If not, the surveillance system may not be 
sensitive enough to detect new emerging resistance 
phenotypes or detect organisms with resistance profiles 
of public-health concern such as vancomycin-refractory 
Staphylococcus aureus, which appear to be rare isolated 
events and not yet reported in Europe [6].  Including 
many centers in a database also allows for a better 
understanding of the idiosyncratic epidemiology of 
certain resistant phenotypes which may be of public- 
health importance [7] and an analysis of the database by 
region, often bringing to attention distinct local trends 
of resistance [8]. Appropriate resistance surveillance 
ultimately needs to be international in its scope. We can 
no longer be complacent about what is happening in 
areas other than our own. Somebody else’s problem 
is our problem: witness the wide dissemination of 
penicillin-refractory Streptococcus pnezrvnoniar [9,10] and 
methicillin-resistant Staphylococcus aureus [ 11 ] across 
Europe and beyond in a relatively short space of 
time. Today in Europe, political unification has erased 
the international frontiers between several countries; 
frontiers which microbes did not recognize anyway. 
Several studies have demonstrated the dangers of having 
a neighbor with a resistance problem, because of the 
migration of resistant clones across international 
frontiers [12,13]. 
In order to allow for the implementation of a 
surveillance system that can be all-encompassing in 
terms of geographic coverage, demographic coverage, 
antibiotics and organisms tested, and to have an 
automated system that is designed and permanently 
integrated as part of the normal routine day-to-day life 
ofour hospitals, we should turn to the clinical laboratory 
itself. This philosophy is simple. Clinical laboratories all 
over Europe isolate, speciate and do susceptibility tests 
on organisms of clinical significance on a daily basis. 
Data derived from these tests are mostly stored in some 
form of computerized laboratory information system 
(LIS), and these microbiological data are used to assist 
in therapeutic choice in patient management within 
that institution. Collectively, such databases within 
clinical laboratories could provide a rich, compre- 
hensive source of data, ideal for the reliable and rapid 
detection and surveillance of antimicrobial resistance. 
Today’s advances in technology, particularly the Internet, 
allow for the collection and utilization of these data 
direct from the clinical laboratory information system 
itself for use in a surveillance system. Bear in mind that 
these are the very same data reported locally to clinicians 
and used in the management of patients and the design 
of local formularies. This approach to surveillance is 
taken by The Surveillance NetworkTM (TSN) and 
WHONet  Program. The LIS data source contains all 
relevant clinical and microbiological information 
necessary for subsequent data-mining, and the capacity 
to provide a permanent infrastructure potentially pro- 
viding surveillance of all microbiological data entered 
into the laboratory database. Information from all 
organisms and drugs tested can be collected on a daily 
‘real-time’ basis, generally with no additional effort for 
the microbiology laboratory workers themselves. With 
this approach, laboratories, and the clinical microbio- 
logists managing them, are returned to the front line 
for detection of resistance phenotypes and trends in 
susceptibility. In this capacity, their responsibility as 
an integral and necessary part of our public-health 
infrastructure is emphasized and nurtured. There have 
been some concerns about the collection of non- 
standardized data. A number of factors can assist in 
overcoming this. First, only laboratories that demon- 
strate microbiological proficiency and good laboratory 
practice in their routine daily work should be included. 
Accreditation, and internal and external quahty control, 
can help with this selection. Second, ensuring that the 
database is appropriately balanced with respect to the 
susceptibility testing methodologies used allows for 
analysis of the database by method and thus comparison 
of methods. And finally, there must be a rigid 
enforcement of a quality control program that includes 
‘expert rules’ that screen all data as they enter the 
database, for microbiological sense, internal quality 
control strain data, the use of appropriate methodology 
and correct interpretation of breakpoints. The rigid 
implementation of these rules is perhaps the key to the 
validity of such a database, as only data that pass the 
screening process or can be substantiated by the refer- 
ring center are permitted to enter the final database 
used for analysis. 
The raison d’etre of any surveillance effort should 
be the utilization of data to assist us in our efforts to 
counteract the problems of increasing bacterial drug 
resistance. For this reason, optimizing access to the 
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susceptibility database is of paramount importance. An 
appropriately designed database is complex and will 
rapidly amass a large amount of data. In order to allow 
analyses of the database, the parameters to be chosen 
will depend entirely on the question asked, which 
should be able to reflect the idiosyncratic interests of 
individual scientists and not be restricted by the 
guardian(s) of the database. We must remember that the 
prescribing clinician is the ultimate target for our 
surveillance attempts, and their access to this data 
should not be limited to that small proportion of the 
potential information that is presented at scientific 
meetings or appears in the peer-reviewed press, so often 
the usual fate of surveillance-derived susceptibility data. 
Thus access and query-capability should be given to at 
least all those who provide data in the first place. In 
this light, the communication power provided by the 
Internet can be harnessed to expose surveillance data 
to a potentially vast audience, for on-line observation 
and analysis. This same communication gateway can be 
used to both collect and give back information in a 
timespan of days rather than months or even years. 
Such technology would provide a formidable capability 
for the rapid detection of emerging resistance or novel 
resistant phenotypes of public-health concern, and a 
tremendously powerful educational tool available to 
technical workers and heads of departments alike, so 
crucial in our attempts to counteract the resistance 
problem. The potential for heightened awareness 
of antibiotic resistance both locally, nationally, and 
internationally enables the clinical microbiologist to be 
aware of what susceptibility profiles to expect in their 
own institute, what not to expect, and what to be on 
the lookout for, skills that can be improved through use 
of the surveillance database itself. In addition, tapping 
directly into the clinical microbiology laboratories and 
working closely with the grass-roots microbiologists 
theniselves will in turn help to stimulate the use of 
more reliable and appropriate protocols for resistance 
detection and provide a tremendous stimulus and tool 
for encouraging the use and development of more 
standardized methodologies. 
I t  is necessary that we have comprehensive inter- 
national resistance surveillance networks that are 
designed and dedicated to assist us in our understanding 
and awareness of antimicrobial drug resistance. In 
Europe, we need a truly all-encompassing surveillance 
initiative with an appropriate geographic coverage and 
a permanent infrastructure working alongside scientists 
and as an integral part of public-health infrastructure. 
Such a network can be achieved using the power of the 
Internet and the advanced information technology 
available today. This computer technology allows the 
design of an essentially automated surveillance process, 
enabling scientists to invest their valuable time and 
energy into better analysis of surveyed data, and 
focusing attention on those aspects of the clinical 
setting that also affect bacterial drug resistance, such as 
information concerning infection control, hospital 
hygiene, and antibiotic usage and consumption. Such 
an achievement will not be easy and is possible only if 
scientists, the medical community and private sector 
investment work hand-in-hand to reach this conmion 
goal 
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